Pilot study of the impact of antiproliferative therapy with everolimus administered orally in the reduction of restenosis after implantation of selfexpandable nitinol stent for treatment of occlusive lesions of the superficial femoral artery / Estudo piloto do impacto da terapia antiproliferativa com everolimus administrado por via oral na diminuição de reestenose após implante de stent auto-expansível de nitinol para tratamento de lesões oclusivas da artéria femoral superficial

AUTOR(ES)

Luis Ramon Virgen Carrillo

DATA DE PUBLICAÇÃO

2009

RESUMO

INTRODUCTION: The implantation of a self-expanding of nitinol stent in the treatment of femoropopliteal occlusive lesions has been associated with a poor outcome in a long term setting. Everolimus administered orally to inhibit restenosis of the stent was investigated recently in animals with good results, but its safety and efficacy has not been studied in humans. The purpose of this pilot study was to evaluate the impact of antiproliferative therapy with everolimus administered orally for 28 days in the reduction of restenosis after implantation of self-expandable nitinol stent for treatment of occlusive lesions of the superficial femoral artery. METHODS AND RESULTS: Thirty-four patients were recruited for this randomized, prospective study. The group that received oral Everolimus was consisted of 15 patients and the group that received no medication was 19 patients. The baseline characteristics and procedure were similar in both groups. All the patients had chronic lower limb ischemia and occlusion of the superficial femoral artery (mean of the lesion of 83.14 mm in the group without medication and 105 mm in the everolimus group). The primary objective of the study was to evaluate the reduction of the average percentage of the diameter of in-stent restenosis six months after angioplasty assessed by quantitative angiography. The in-stent mean percent diameter stenosis was 46.9% in the group treated with everolimus and 44.5% in the group that received no medication (p = 0.81). There were no serious side effects seen in either group in the clinical follow up at 24 months. There was no significant difference between groups in relation to clinical events. The primary patency, assisted primary and secondary in 24 months was 42%, 74% and 79% in the group without medication and 27%, 73% and 73% in the group treated with Everolimus. CONCLUSION: Everolimus administered orally for 28 consecutive days to stent implantation in high doses proves to be safe and well tolerated, with low rate of side effects, but it is not effective in reducing the average percentage of diameter of in-stent restenosis in patients with implantation of self-expandable nitinol stent in complex occlusive lesions of the superficial femoral artery.

ASSUNTO(S)

angiografia implantation of a vascular prosthesis/methods angiography ischemia isquemia femoral artery/pathology extremidade inferior everolimus/therapeutic use implante de prótese vascular/métodos lower extremity everolimus/uso terapêutico artéria femoral/patologia

Documentos Relacionados

• Experiência com o uso de endoprótese auto-expansível (stent) introduzida através da artéria femoral para tratamento das doenças da aorta torácica descendente
• Confecção e avaliação de órtese de nitinol auto-expansível com aplicação em vias aéreas
• Self-expandable nitinol stent placement in homocysteinemic porcine aorta
• Recanalização de estenose esofágica refratária à dilatação endoscópica pelo uso temporário de prótese plástica auto-expansível
• Endoprótese auto-expansível de malha de poliéster revestida por silicone (Polyflex®) no tratamento de estenoses traqueais não-cirúrgicas